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Abstract
Introduction—Huntington’s disease (HD) is a genetic neurodegenerative disorder that primarily 
affects striatal neurons. Striatal volume loss is present years before clinical diagnosis; however, 
white matter degradation may also occur prior to diagnosis. Diffusion-weighted imaging (DWI) 
can measure microstructural changes associated with degeneration that precede macrostructural 
changes. DWI derived measures enhance understanding of degeneration in prodromal HD (pre-
HD).
Methods—As part of the PREDICT-HD study, N =191 pre-HD individuals and 70 healthy 
controls underwent two or more (baseline and 1–5 year follow-up) DWI, with n =649 total 
sessions. Images were processed using cutting-edge DWI analysis methods for large multicenter 
studies. Diffusion tensor imaging (DTI) metrics were computed in selected tracts connecting the 
primary motor, primary somato-sensory, and premotor areas of the cortex with the subcortical 
caudate and putamen. Pre-HD participants were divided into three CAG-Age Product (CAP) score 
groups reflecting clinical diagnosis probability (low, medium, or high probabilities). Baseline and 
longitudinal group differences were examined using linear mixed models.
Results—Cross-sectional and longitudinal differences in DTI measures were present in all three 
CAP groups compared with controls. The high CAP group was most affected.
*Correspondence to: Jane S. Paulsen; The University of Iowa, 305 Medical Education Building, Iowa City, IA 52242., jane-
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Conclusions—This is the largest longitudinal DWI study of pre-HD to date. Findings showed 
DTI differences, consistent with white matter degeneration, were present up to a decade before 
predicted HD diagnosis. Our findings indicate a unique role for disrupted connectivity between the 
pre-motor area and the putamen, which may be closely tied to the onset of motor symptoms in 
HD.
Keywords
Huntington disease; disease progression; prodromal; white matter; diffusion tractography; 
diffusion magnetic resonance imaging; multicenter study; image processing; computer-assisted
INTRODUCTION
In contrast to other neurodegenerative diseases, such as Parkinson’s or Alzheimer’s, 
Huntington’s Disease (HD) occurs as the result of a single known genetic mutation, which 
allows researchers to study individuals with the mutant Htt genotype prior to diagnosis (pre-
HD) [Long et al., 2011; Paulsen et al., 2001, 2006a, 2008; Tabrizi et al., 2009, 2011, 2012]. 
During the pre-HD phase, individuals do not manifest the characteristic motor symptoms 
necessary for a diagnosis, but they have been shown to exhibit mild sub-clinical cognitive, 
psychiatric and motor deficits [Ross et al., 2014]. Furthermore, imaging studies have shown 
that volume reductions in the striatum, particularly within the caudate, can be observed as 
many as 10 years before diagnosis in pre-HD individuals [Bohanna et al., 2008; Harris et al., 
1999; Thieben et al., 2002]. Volume reductions in the globus pallidus [Harris et al., 1999; 
Thieben et al., 2002] and thalamus [Harris et al., 1999; Paulsen et al., 2006b] have also been 
observed, but occur closer to diagnosis [Bohanna et al., 2008; Thieben et al., 2002]. It is less 
clear whether cortical thinning occurs in pre-HD. While some studies have found decreased 
cortical thickness in pre-HD [Bohanna et al., 2008; Nopoulos et al., 2007; Rosas et al., 
2005], others have found increased grey matter volume [Aylward et al., 1996, 1998; Paulsen 
et al., 2006b]. The relatively large longitudinal TRACK-HD study failed to find differences 
in cortical volumes at baseline and 12 months [Tabrizi et al., 2009, 2011] in pre-HD, but did 
find reduced cortical thickness in occipital areas in pre-HD individuals who were closest to 
diagnosis at 24 months [Tabrizi et al., 2012], suggesting that cortical thickness changes may 
not be tied to motor symptom onset or that they occur only as secondary collateral damage 
measurable late in the pre-HD stage of the illness.
Substantial changes in cortical white matter are known to occur in pre-HD individuals. 
Overall white matter has been shown to be reduced in the area surrounding the striatum 
[Tabrizi et al., 2009, 2011, 2012] and throughout the brain [Paulsen et al., 2006b]. Diffusion 
tensor imaging (DTI) studies have further provided evidence of white matter degeneration in 
terms of reduced fractional anisotropy (FA) and increased radial diffusivity (RD). Reduced 
FA has been observed in frontal white matter [Rosas et al., 2006; Phillips et al., 2013], 
surrounding the striatum [Magnotta et al., 2009; Rosas et al., 2006; Stoffers et al., 2010], the 
thalamus [Rosas et al., 2006; Stoffers et al., 2010], corpus callosum [Phillips et al., 2013; 
Stoffers et al., 2010], and in parietal and occipital white matter [Phillips et al., 2013]. 
Increased RD has been shown to accompany reduced FA in several of these regions 
including the corpus callosum [Phillips et al., 2013; Stoffers et al., 2010], frontal tracts 
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[Phillips et al., 2014; Poudel et al., 2014], thalamic tracts [Phillips et al., 2014; Stoffers et 
al., 2010], and surrounding the striatum [Stoffers et al., 2010]. Likewise, increases in axial 
diffusivity (AD) have been observed in many of the same tracts [Phillips et al., 2014; 
Stoffers et al., 2010]. Taken together, these findings suggest that DTI differences between 
healthy controls and pre-HD individuals reflect degeneration at the cellular level and impact 
white matter tract integrity. Furthermore, these changes may occur in the absence of volume 
changes within the tissue, suggesting that DTI measures may provide an earlier indicator of 
neurodegeneration than volume measurements.
Despite an accumulation of results showing cross-sectional DTI white matter abnormalities 
in pre-HD, longitudinal study findings have been inconsistent. Two studies failed to find 
abnormal 12- to 30-month changes in DTI [Odish et al., 2015; Poudel et al., 2015] whereas 
one more recent finding showed DTI changes in 64 preHD over 2 years [Harrington et al., 
2016]. The purpose of the current study was to examine cross-sectional and longitudinal 
diffusion weighted imaging (DWI) in the largest sample of pre-HD studied to date.
We assessed cortico-striate connectivity using longitudinal DTI data collected as part of the 
multi-site PREDICT-HD study [Paulsen et al., 2014b]. Based on known changes in clinical 
presentations of sensory and motor symptoms, we expect that DTI indicators of WM 
degeneration including increased mean diffusivity (MD), decreased fractional anisotropy 
(FA), increased axial diffusivity (AD), and increased radial diffusivity (RD) will be present 
in tracts between sensory and motor regions of the cortex and the striatum in pre-HD 
participants. We also expect that this degeneration will be most severe in participants who 
are closer to HD diagnosis (i.e., having a high probability of diagnosis). Finally, we predict 
that these changes will be progressive, with signs of degeneration becoming more 
pronounced in pre-HD participants over time.
MATERIAL AND METHODS
Participants
Participants were a subset of the multi-site PREDICT-HD study [Paulsen et al., 2014b] data 
that included 191 individuals with pre-manifest HD and 70 healthy controls. All participants 
were right handed and underwent at least two longitudinal imaging sessions, resulting in a 
total of 474 pre-HD and 175 healthy control imaging sessions.
Additional demographic characteristics for this sample are shown in Table I. Participants 
with pre-HD were assigned into CAP score groups (low, medium, high) at study entry 
[Zhang et al., 2011]. The groups did not differ in terms of number of imaging sessions 
performed per participant, overall duration of time between imaging sessions, or education. 
Groups differed significantly with regards to both age and sex. Because age is used in the 
calculation of the CAP score, differences between the pre-HD CAP groups were expected 
(CAP is not computed for controls). With regards to sex, the High CAP group imaging 
sessions had a higher proportion of males than did the other groups.
PREDICT-HD exclusion criteria included (a) sufficient motor signs for a motor diagnosis at 
study entry; (b) history of traumatic brain injury or other central nervous system injury or 
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diseases; (c) pacemakers or metallic implants; (d) prescribed antipsychotic or phenothiazine-
derivative antiemetic medication in the past six months; and (e) clinical evidence of unstable 
medical or psychiatric illness.
CAP Score
The presence of the pathogenic form of the Htt gene was confirmed through genetic testing. 
The number of CAG repeats and subject age were used to calculate the CAG-Age Product 
(CAP) score [Zhang et al., 2011] at study entry and for each imaging session using the 
formula CAP =Age0 × (CAG − 33.66), with Age0 indicating age in years at the time of the 
first diffusion-weighted imaging (DWI) scan session (Participant may have entered 
PREDICT-HD several years prior to this date). CAP score has been validated as a proxy for 
time-to-diagnosis in HD with larger scores indicating a higher probability of near-future 
motor diagnosis [Zhang et al., 2011].
Consistent with previous PREDICT-HD data analysis [Paulsen et al., 2013], the pre-HD 
group was divided into three sub-groups based on their CAP score calculated at the time of 
their first DWI session. The Low CAP group (CAP score <287.16) consisted of 50 
participants; the Medium CAP group (287.16 <CAP score <367.12) included 56 
participants; and the High CAP group (CAP score- >367.12) included 85 participants. 
Participants from the Low, Medium, and High CAP groups underwent a total of 121, 144, 
and 209 imaging sessions, respectively.
Imaging Parameters
A total of 649 T1 and T2-weighted anatomical and diffusion-weighted images were acquired 
on 3T scanners at 15 sites, representing 3 scanner manufacturers (GE, Phillips, and 
Siemens). Due to varying scanning site capabilities and support resource, a minimum set of 
criteria were specified for merging the DWI data sets from different sites was established: 
(1) Only DWI data sets with more than 28 quality approved gradients, (2) voxel volume was 
required to be less than 9.6 cubic mm with a maximum voxel length of 2.4mm, (3) All 
directional gradients needed to be within 2% of 1,000 for their B-Value, and (4) anatomical 
coverage need to completely include all the tracts of interest. The most frequently used MRI 
acquisition parameters are provided in Table II, and all scanner parameters are supplied as 
supplemental materials. After visual inspection of all images, we excluded 13 T2-weighted 
MRI scans, resulting in 636 multimodal and 13 single modal inputs for structural MRI 
processing. Processed T2-weighted images were then used along with DWI data in the 
diffusion analysis pipeline when available and the T1-weighted images were used for the 13 
sessions where the T2-weighted images were not available.
Image Processing
Structural and diffusion-weighted MR images were processed using the BRAINSTools suite 
(https://github.com/BRAINSia/BRAINSTools.git) and ANTs packages [Avants et al., 2009]. 
An extensible processing pipeline was developed in Nipype [Gorgolewski et al., 2011] that 
utilizes high performance computing resources in order to achieve time-efficient data 
processing and tractography analysis on large-scale multicenter diffusion-weighted images.
Shaffer et al. Page 4
Hum Brain Mapp. Author manuscript; available in PMC 2017 April 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Structural MRI processing—Structural MR Images [T2-weighted (T2-w) and/or T1-
weighted (T1-w) images] were utilized to fix susceptibility-induced anatomical distortions in 
diffusion-weighted imaging (DWI) data and provide precise anatomical labeling for DWI 
processing and analysis. All available structural modalities (T1- and when available T2-
weighted images) from each dataset were processed jointly to improve the robustness of the 
processing using complimentary information provided by multiple modalities. In the 13 
cases where the T2 image was not available a T1-only data processing was performed to 
identify anatomical brain regions. The T1-only morphometric processing provided 
sufficient, albeit sub-optimal, segmentations for the subsequent tracts of interest extraction 
method. First, structural MR data were spatially normalized to a common reference 
orientation defined by anterior commissure-posterior commissure (AC-PC) line and inter-
hemispheric fissure [Ghayoor et al., 2013; Lu and Johnson, 2010]. The images were then 
processed through an Expectation Maximization (EM) and a fuzzy k-Nearest Neighbor 
(KNN) tissue classification that incorporates bias-field correction, image registration, and 
tissue classification [Ghayoor et al., 2016; Kim and Johnson, 2013]. Whole brain 
segmentation (i.e., labeling) was performed on the bias-field corrected T1-w and T2-w 
images using the Multi-Atlas Label Fusion method [Kim et al., 2015]. The whole brain 
segmentation resulted in 180 independently labeled regions that are consistent with the 
FreeSurfer Atlas labeling scheme.
DWI processing—DWI processing leverages the results of structural MRI processing as 
illustrated in Supporting Information Figure S1. The DWI processing first employed the 
quality control (QC) procedures described in our previous works [Matsui, 2014; Oguz et al., 
2014] to prepare DWI scans by removing slice-wise and interlace artifacts as well as 
correcting for eddy-current and motion artifacts. The QC’ed DWI scans were further 
processed to integrate susceptibility artifact correction using a non-linear constrained 
registration in the phase-encoding direction available from the ANTs packages [Avants et 
al., 2009]. The constrained registration only allows warping within the plane (i.e., within 
image slice) for the phase encoding direction, and is primarily used to improve anatomical 
alignment of the DWI to the morphometric scans.
Due to the wide range of available gradient directions and/or replicated gradient directions 
available from different sites, we treat each data set as a sparse sampling (or oversampling in 
the HARDI data sets). We used our compressed sensing algorithm [Michailovich et al., 
2011] to reconstruct the DWI signal from the sparse set of measurements, acquired at all 
sites. Specifically, this methodology allowed us to construct a normalized data representation 
of canonical set of the same 81 gradient directions for each DWI image. This approach has 
been shown to improve measurements of multiple fiber orientations even from the few 
gradient directions acquired [Rathi et al., 2011].
DTI Tractography
A whole brain tractography was performed using a multi-fiber model to improve sensitivity 
in anatomical regions of crossing fibers. The two-tensor unscented Kalman filter 
tractography (UKFt) method was employed with free-water elimination to address partial 
volume effects near ventricles or cortex [Baumgartner et al., 2012; Malcolm et al., 2010]. 
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UKFt parameter settings were determined via empirical testing on a subset of the dataset. In 
order to maximize sensitivity to the cortico-striate connections, the fractional anisotropy and 
generalized anisotropy thresholds for seeding/stopping tractography were set to 0.06, and 10 
tractography seeds were initiated per voxel.
Reliability of DWI data is extremely important for studies that depend upon the 
collaboration of multiple imaging sites. All tractography results (for all subjects) underwent 
a quality check using the White Matter Analysis [O’Donnell and Westin, 2007] quality 
control tool, which enables rapid visual inspections of tractography results by human 
experts. All tractography results were validated by examining features in the arcuate 
fasciculus, uncinate fasciculus, inferior longitudinal fasciculus, cingulum, corpus callosum, 
corona radiata, and brain stem. Supporting Information Figure S2 shows example sagittal 
views for (a) correct and (b) incorrect tractography. Sessions that failed this check were 
excluded.
Cortico-striatal tracts were defined using the White Matter Query Language (WMQL) 
[Wassermann et al., 2013, 2016] using per-participant whole-brain segmentation and 
tractography results. The morphometric whole-brain segmentations provide anatomically 
relevant regions of interest, the whole-brain tractography provides global white matter tract 
information, and the WMQL provides an extensible user-friendly tool for the automated 
dissection of human white matter. Tracts were created for each hemisphere between cortex 
regions including primary motor cortex (precentral gyrus), primary somatosensory cortex 
(postcentral gyrus), and premotor area (posterior middle frontal gyrus and opercular region 
of inferior frontal gyrus); and striatal regions including the caudate and putamen, resulting in 
a total of 6 tracts for each hemisphere (primary motor-caudate; primary sensory-caudate; 
premotor-caudate; primary motor-putamen; primary sensory-putamen; and premotor-
putamen). These tracts are shown in Figure 1. Under the assumption that the biological tract 
of interest is composed primarily of non-crossing fibers, rotationally invariant measures 
within a given tract were computed only from the primary tensor of the 2-Tensor model. For 
the remainder of this manuscript MD, FA, AD, and RD measures are computed from the 
primary tensor (i.e., the tensor along the tract) of the 2-tensor model within each tract.
Statistical Analysis
Differences in mean baseline level (intercept) and mean rate of longitudinal change (slope) 
between CAP groups were analyzed using linear mixed models (LMMs) for longitudinal 
data [Verbeke and Molenberghs, 2000]. Two models, a full model with CAP group-specific 
intercepts and slopes, and a reduced model that did not have CAP group-specific effects (i.e., 
the same slope and intercept was shared amongst the groups) were fit for each outcome 
variable (tract of interest/DTI measure). These two models were compared via a likelihood 
ratio test (LRT) to address the omnibus null hypothesis of no group differences in intercepts 
or slopes. Measurements from tract-DTI measure pairings where these two models did not 
differ were excluded from the results.
Both models included a time metric measured as years in the study (0 =study entry) and 
additional covariates of sex, years of education, and modality of the scan. In order to account 
for correlation due to repeated measurements of the same participants, random intercepts 
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were included for each participant in the model. Furthermore, random site intercepts were 
included to account for correlation due to a common scanner or other common site-specific 
features. Maximum likelihood methods were used for estimation under normality 
assumptions for the random effects and random error [Verbeke and Molenberghs, 2000]. 
LMMs provide unbiased estimates for the parameters of interest with missing data, provided 
the missing data mechanism is at least missing at random (MAR).
Baseline (intercept) and longitudinal (slope) contrasts between CAP groups were performed 
using general linear hypothesis testing.
Stacked analysis—In order to compare the longitudinal relationship between DTI 
measures and CAP group with the longitudinal relationship between striatal volume and 
CAP group (i.e., examining two outcomes simultaneously), we performed a second 
“stacked” regression analysis. Simultaneous analysis of scalar DTI and brain structural 
volume measurements allows the direct statistical comparison of the baseline and 
longitudinal values of the outcome variables by group. For example, we might examine if 
MD and putamen volumes deteriorate at the same absolute rate (but in different directions) 
in the High CAP group, but at different absolute rates in the Low CAP group.
The stacked analysis was performed for tracts where DTI differences between CAP groups 
were present in the first analysis. In order to analyze two outcome variables simultaneously, 
the outcome measures and corresponding covariate data were converted to stacked format, as 
discussed by Long [2011, chap. 13]. For instance, in the above example, each subject’s 
vector of repeated MD measurements was concatenated with their vector of repeated 
putamen volume measurements. The same was done for the covariate matrices (design 
matrices), with the same covariates included in the matrices as the first analysis. Dummy 
variables were constructed to code for each outcome and corresponding covariates, which 
allows for the simultaneous estimation of baseline and longitudinal values for the two 
outcomes (in the above example, MD and putamen). The main advantage is that the 
covariance among the outcome baseline value and the outcome longitudinal value can be 
estimated allowing for direct statistical comparisons (e.g., a confidence interval can be 
computed for the difference between the MD slope and the putamen slope).
Similar to the first analyses, CAP group coding was included in the covariate matrix to 
examine potential group differences. The so-called stacked LMM described above includes 
random effects for subject baseline values and sites of each outcome, and the random effects 
are assumed to have a joint-normal distribution with a general covariance matrix. To account 
for different scales of the outcomes, the separate outcome vectors were standardized by 
subtracting the mean of the vector (computed among participants and times), and dividing 
by the standard deviation of the vector. The scaling was performed prior to concatenating, so 
that comparisons across domains were more meaningful, not being affected by the 
magnitude of the measurement scales (additional details of the stacked LMM can be found 
in the Supporting Information).
Furthermore, in order to ensure that the average trajectories of the two outcome measures in 
the more progressed groups (e.g., the High CAP group) were comparable, the values for 
Shaffer et al. Page 7
Hum Brain Mapp. Author manuscript; available in PMC 2017 April 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
MD, AD, and RD measures were multiplied by −1 when necessary. The result is that the 
average DTI and brain volume longitudinal changes in the High CAP group have a negative 
value, allowing direct comparison of differences in magnitude for longitudinal decline and 
baseline values by outcome within the same CAP group, while still accurately estimating 
parameters denoting CAP group-specific slope and CAP group-specific intercept within 
domain.
RESULTS
Regression Analysis Comparing DTI Measures with CAP Group
The relationship between each DTI measure (MD, FA, AD, RD) and CAP group (healthy 
control, low, medium, and high) was assessed using LMM. Here we report the results only 
for tracts and measures where the full model significantly differed from the null model.
Baseline (intercept) differences in DTI measures—Group differences in baseline 
values are reported in Table III and are shown in Figure 2a. These results reflect baseline 
differences between groups for each measure.
Primary Motor-Caudate: The High CAP group had significantly lower mean FA compared 
with the Low CAP group in the right primary motor cortex-caudate tract. There were no 
other significant differences in the motor-caudate tracts.
Premotor-Caudate: The High CAP group had significantly higher MD, lower FA, and 
higher RD compared with the healthy control and Low CAP groups in both left and right 
premotor-caudate tracts. Similarly, the Medium CAP group had significantly higher MD 
than the Low CAP group and lower FA than the healthy control group in the left premotor-
caudate tract as well as lower FA and higher RD than the Low CAP group in both left and 
right premotor-caudate tracts.
Primary Motor-Putamen: The High CAP group had significantly higher MD than the 
control and Low CAP group in both left and right primary motor-putamen tracts. Similarly, 
the High CAP group had higher AD than the Low CAP group in the right primary motor-
putamen tract and higher RD than healthy controls in the left primary motor-putamen tract.
Premotor-Putamen: The High CAP group showed significantly greater MD than healthy 
controls and the Low CAP group in bilateral premotor-putamen tracts as well as greater MD 
than the Medium CAP group on the right. Lower FA was only present in the High CAP 
group compared with healthy controls on the left, while higher AD was found in the High 
CAP group compared with healthy controls and the Medium CAP group on the right and in 
the High CAP group compared with the Low CAP group on the left. Increased RD was 
present in the High CAP group bilaterally compared with healthy controls and in the 
Medium CAP group compared with healthy controls and the High CAP group compared 
with the Low CAP group in the left premotor-putamen tract.
Sensory-Putamen: MD was significantly higher in the High CAP group compared with the 
healthy control group and to the Low CAP group in bilateral sensory-putamen tracts. The 
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High CAP group also had higher MD than the Medium CAP group in the left sensory-
putamen tract while the Medium group had higher MD than healthy controls and the Low 
CAP group in the right sensory-putamen tract. The High CAP group also showed higher AD 
than healthy controls and the Low CAP group in the right sensory-putamen cortex and 
higher RD than the healthy control group and Low CAP group in bilateral sensory-putamen 
tracts and higher RD than the Medium CAP group in the left sensory-putamen tract.
Longitudinal (slope) differences in DTI measures—Group differences in 
longitudinal values (i.e., slopes), or change over time are reported in Table IV and are shown 
in Figure 2b. These results reflect differences in change over time between groups for each 
measure.
Premotor-Caudate: The High CAP group had a significantly faster decrease in FA and 
significantly faster increase RD compared with the healthy control group in the right 
premotor-caudate tract.
Primary Motor-Putamen: The High CAP group had a significantly faster increase in AD 
compared with healthy controls in bilateral primary motor-putamen tracts.
Premotor-Putamen: Significantly faster increases in MD and RD were present in the right 
premotor-putamen tract in both the Medium and High CAP groups compared with the 
healthy control and Low CAP groups. The High CAP group showed a significantly faster 
increase in FA in the left premotor-putamen tract compared with healthy controls and the 
Low CAP group, while both the Medium and High CAP groups showed a significantly 
faster decrease in FA compared with healthy controls in the right premotor-putamen tract. A 
significantly faster increase in AD was present in the High CAP group compared with the 
Low CAP group bilaterally, in the High CAP group compared with healthy controls on the 
left, and in the Medium CAP group compared with the Low CAP group on the right. A 
significantly faster decrease in AD was present in the Low CAP group compared with 
healthy controls in the right premotor-putamen tract.
Sensory-Putamen: A significantly faster increase in AD was present in the High CAP 
group compared with healthy controls bilaterally, in both the High and Medium CAP groups 
compared with the Low group on the left, and in the High CAP group compared with the 
Medium CAP group on the right.
Stacked Regression Analysis for Comparing DTI Measures with Striatal Volume
Baseline (intercept) differences between DTI measures and striatal volume—
We first consider baseline differences among pairs of outcome variables (DTI measure, 
striatal volume) by group (controls, low, medium, and high). The results of comparisons 
between the baseline values for these pairs of measures are shown in Table V.
Healthy Controls: There were no significant differences in the baseline values between the 
DTI measures and striatal volume for the healthy control group.
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Low CAP: In the Low CAP group, the baseline value for FA in the right primary motor-
caudate and baseline value for RD in the left premotor-putamen tracts were significantly 
lower than the baseline value for striatal volume.
Medium CAP: Within the Medium CAP group, the baseline values for MD was 
significantly lower than baseline striatal volume in bilateral premotor-caudate, bilateral 
primary motor-putamen, bilateral premotor-putamen, and bilateral sensory-putamen tracts; 
for FA in right primary motor-caudate, bilateral premotor-caudate, and bilateral premotor-
putamen tracts; for AD in bilateral primary motor-putamen, bilateral premotor-putamen, and 
bilateral sensory-putamen tracts; and for RD in bilateral premotor-caudate, left primary 
motor-putamen, bilateral premotor-putamen, and bilateral sensory-putamen tracts.
The difference between these measures was wider in the Medium CAP group than the Low 
CAP group for MD and AD in bilateral primary motor-putamen, bilateral premotor-
putamen, and bilateral sensory-putamen tracts; for FA in bilateral premotor-putamen tracts; 
and for RD in bilateral premotor-caudate, left primary motor-putamen, bilateral premotor-
putamen, and bilateral sensory-putamen tracts.
High CAP: Within the High CAP group, the baselines values for MD was significantly 
lower than the baseline striatal volume in bilateral premotor-caudate, left primary motor-
putamen, bilateral premotor-putamen, and bilateral sensory putamen tracts; for FA in right 
primary motor-caudate, bilateral premotor-caudate, and bilateral premotor-putamen tracts; 
for AD in bilateral primary motor-putamen, bilateral premotor-putamen, and bilateral 
sensory-putamen tracts; and for RD in bilateral premotor-caudate, left primary motor-
putamen, bilateral premotor-putamen, and bilateral sensory-putamen tracts. The difference 
between these measures was wider in the High CAP group than the Low CAP group for MD 
in bilateral premotor-caudate, primary motor-putamen, premotor-putamen, and bilateral 
sensory-putamen tracts; for FA in right primary motor-caudate, bilateral premotor-caudate, 
and bilateral premotor-putamen tracts; for AD in bilateral primary motor-putamen, bilateral 
premotor-putamen, and bilateral sensory-putamen tracts; and for RD in bilateral premotor-
caudate, left primary motor-putamen, bilateral premotor-putamen, and bilateral sensory-
putamen tracts.
There was also a wider difference between the baseline values for DTI measures and striatal 
volume in the High CAP group compared with the Medium CAP group for MD in bilateral 
premotor-caudate, left motor-putamen, bilateral premotor-putamen, and bilateral sensory-
putamen tracts; for FA in right motor-caudate, bilateral premotor-caudate, and bilateral 
premotor-putamen tracts; for AD in bilateral motor-putamen, bilateral premotor-putamen, 
and bilateral sensory-putamen tracts; and for RD in bilateral premotor-caudate, left motor-
putamen, bilateral premotor-putamen, and bilateral sensory-putamen tracts.
Longitudinal (slope) differences between DTI measures and striatal volume—
We now turn to longitudinal differences in pairs of variables by group. The results for these 
contrasts are shown in Table VI.
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Healthy Controls: There were significant longitudinal differences in healthy controls 
between striatal volume and DTI measures for MD in the right premotor-caudate, right 
motor-putamen, and right premotor-putamen tracts; for FA in bilateral premotor-caudate and 
right premotor-putamen tracts; for AD in bilateral motor-putamen and right premotor-
putamen tracts; and for RD in right premotor-caudate and right premotor-putamen tracts.
Low CAP: Within the Low CAP group, the longitudinal changes were smaller for MD in 
bilateral premotor-caudate, bilateral motor-putamen, bilateral premotor-putamen, and 
bilateral sensory-putamen tracts; for FA in right motor-caudate, bilateral premotor-caudate, 
and bilateral premotor-putamen tracts; for AD in bilateral motor-putamen, bilateral 
premotor-putamen, and bilateral sensory-putamen tracts; and for RD in bilateral premotor-
caudate, left motor putamen, bilateral premotor-putamen, and bilateral sensory-putamen 
tracts than the longitudinal change for striatal volume.
Medium CAP: Within the Medium CAP group, the longitudinal changes were smaller for 
MD in bilateral premotor-caudate, right motor-putamen, left premotor-putamen, and right 
sensory-putamen tracts; for FA in right motor-caudate, bilateral premotor-caudate and 
bilateral premotor-putamen tracts; for AD in bilateral motor-putamen and bilateral sensory-
putamen tracts; and for RD in bilateral premotor-caudate, left premotor-putamen, and 
bilateral sensory-putamen tracts than the longitudinal change for striatal volume.
The difference between these measures was wider in the Medium CAP group than the Low 
CAP group for MD in right premotor-putamen and left sensory-putamen tracts; for FA in the 
left premotor-putamen tract; for AD in the bilateral premotor-putamen and left sensory-
putamen tracts; and for RD in the right premotor-putamen tract.
High CAP: Within the High CAP group, the longitudinal changes were smaller for MD in 
right and right sensory-putamen tracts; for FA in left premotor-caudate and bilateral 
premotor-putamen tracts; for AD in bilateral motor-putamen, right premotor-putamen, and 
bilateral sensory-putamen tracts; and for RD in left premotor-putamen and right sensory-
putamen tracts than the longitudinal change for striatal volume.
The difference between these measures was wider in the High CAP group than the Low 
CAP group for MD in left premotor-caudate, right premotor-putamen, and left sensory-
putamen tracts; for FA in bilateral premotor-caudate tracts; for AD in left motor-putamen 
and left premotor-putamen tracts; and for RD in bilateral premotor-caudate and right 
premotor-putamen tracts.
There was also a wider baseline difference between DTI measures and striatal volume in the 
High CAP group compared with the Medium CAP group for MD in the left premotor-
caudate tract; for FA in bilateral premotor-caudate tracts; and for RD in bilateral premotor-
caudate tracts.
DISCUSSION
To our knowledge, this is the largest study to examine longitudinal diffusion-weighted 
imaging data in prodromal and early HD. We used data from the PREDICT-HD study in 
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order to test whether (a) white matter degeneration was present in the cortico-striate tracts 
connecting premotor, motor, and somatosensory cortices to the caudate and putamen of pre-
HD individuals and (b) whether longitudinal worsening occurred. Our findings demonstrate 
that highly significant alterations in white matter tracts connecting sensory and motor cortex 
regions to the striatum are present in pre-HD individuals. Our findings also demonstrate that 
these disease burden-related changes accelerate as the predicted diagnosis time is 
approached, with pre-HD individuals showing changes in DTI measures that indicate 
increasing white matter degeneration over time. Furthermore, while our findings suggest that 
the severity is greatest in pre-HD individuals who are closest to diagnosis, significant 
baseline and longitudinal changes in DTI measures were present in both the Low and 
Medium CAP groups.
Reductions in striatal volume in pre-HD are known to occur as many as 10 years before 
clinical diagnosis [Aylward et al., 1996; Douaud et al., 2006; Harris et al., 1999]. However, 
more recently it has become clear that changes in both structural [Matsui et al., 2014, 2015; 
Paulsen et al., 2010; Poudel et al., 2014] and functional connectivity [Dogan et al., 2015] are 
also present in pre-HD. In recent work by our group, we identified altered prefrontal DTI 
measures [Matsui et al., 2014, 2015] in pre-HD while, in a similar study Poudel et al. [2014] 
also found altered DTI measures in tracts connecting the prefrontal cortex, primary motor 
cortex, and striatum in pre-HD individuals who were close to diagnosis. In this study, we 
expanded upon previous findings showing altered DTI in pre-HD by investigating cortical 
regions involved specifically in motor function. We analyzed longitudinal data in order to 
test whether changes in these regions over time were related to disease progression (CAP 
group). Our findings showed that changes in DTI measures consistent with white matter 
degeneration (increased MD, RD, AD; decreased FA) are present in every stage of 
prodromal HD and become more pronounced as participants approach predicted diagnosis. 
The greatest difference in longitudinal change was between the High CAP group and healthy 
controls, indicating that the group with the greatest prodromal disease progression also had 
the fastest rate of deterioration. The longitudinal changes were also significantly different for 
several tracts in the Medium CAP group, which is consistent with the findings of Matsui et 
al. [2014, 2015] and Poudel et al. [2014]. Interestingly, we also found that the Low CAP 
group showed greater MD and RD than healthy controls in the right premotor area–putamen 
tract, suggesting that DTI changes occurred earlier than what was shown in the previous 
studies. Given that the estimated time to diagnosis for the Low CAP group is greater than 13 
years, these findings indicated that DTI changes within these cortico-striate tracts might 
begin many more years before clinical diagnosis than previously indicated.
In addition to examining the longitudinal change of individual DTI variable over time, we 
also compared changes of DTI and volume measures within each CAP group. Comparisons 
between the baseline values of these measures indicated that DWI measures showed less 
degeneration in all four groups. Comparisons among the longitudinal changes indicated that 
DWI measures changed more slowly than volume measures. In other words, reductions in 
striatal volume were more pronounced and worsened more quickly, even during normal 
aging. However, these differences were more pronounced in the Low and Medium CAP 
groups rather than in the High CAP group. This is consistent with our findings showing 
changes in DTI measures occurred most rapidly in the High CAP group. The results of this 
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analysis also indicated that DTI measures and striatal volume measures show differential 
relationships with CAP group (i.e., follow a different trajectory), indicating that DTI 
measures may provide additional (and independent) information that is not provided by 
changes in striatal volume.
While we considered that DTI changes might be present before volume changes due to the 
difference in sensitivity of volume vs. diffusion-weighted imaging techniques, our results 
instead show that striatal volume changes precede white matter changes. Anatomically, our 
tracts of interest are primarily comprised of striatal afferents and so our results suggest that 
(1) Striatal volume loss may lead to degeneration in cortical afferents several years prior to 
HD diagnosis and (2) that loss of striatal input may be a key aspect of motor symptom onset. 
Future work to disentangle the relationship between striatal afferents and efferents may be 
difficult, as these circuits are generally thought to form a loop (cortex → striatum → 
pallidum → thalamus → cortex); however these results may suggest that methods for 
maintaining the integrity of cortico-striatal tracts may help to alleviate or delay the onset of 
motor symptoms in HD.
Differences among the three CAP groups were examined in order to determine whether there 
was a between-group difference in the relationship between DTI measures and striatal 
volume. Overall, this analysis indicated that as the pre-HD stage progressed, baseline 
differences between the measures grew larger while longitudinal change differences became 
smaller. That is, the High CAP group showed the greatest baseline difference, but also 
showed a smaller longitudinal difference between DTI and volume measures. This suggests 
that either striatal volume changes more slowly or that DTI measures change more rapidly in 
the High CAP group than the other CAP groups. However, given the baseline differences 
between CAP groups, it is likely that this is specifically due to changes in DTI measures, 
suggesting that white matter degeneration starts later and then occurs more quickly than 
volume changes later in the pre-HD phase of the illness.
Anatomically, connectivity with the putamen was more disrupted than connectivity with the 
caudate in our tracts of interest. We observed disease-related DTI differences within all six 
tracts-of-interest that connected our cortical regions-of-interest to the putamen, whereas 
disease-related DTI differences were only observed in left and right premotor area-caudate 
tracts. Given that neurodegeneration in HD is thought to originate in the caudate and to 
progress into the putamen [Aylward et al., 1996], we may have expected a greater severity of 
white matter degeneration in tracts connected with the caudate. However, caudate afferents 
primarily originate in multimodal association areas whereas the bulk of putamen afferents 
originate in primary and secondary sensory cortices including the premotor area, primary 
motor cortex, and primary somatosensory cortex [Leh et al., 2007; Purves et al., 2001]. It is 
therefore encouraging that our results align with known anatomical connectivity involving 
these regions. Furthermore, caudate degeneration has been shown to be less severe than 
putamen degeneration in HD [Harris et al., 1992] which may also explain these findings. 
Recent publications [Paulsen et al., 2014a,b; Tabrizi et al., 2013] have also noted that 
putamen volumes are a more reliable predictor of disease state than caudate volumes, which 
may have introduced additional variance in volumetric assessment.
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However, our findings, combined with the understanding that volume loss in the putamen 
occurs closer to diagnosis [Aylward et al., 1996], suggest that motor impairment due to the 
loss of connectivity between motor areas and the putamen may ultimately be responsible for 
clinical diagnosis. A few prior studies also support such an interpretation. For example, 
Aylward et al. [2012] found that putamen volume was the strongest predictor of disease 
progression when comparing CAP-score matched prodromal and diagnosed HD individuals. 
Likewise, a functional connectivity study carried out by Dogan et al. [2015] showed that 
connectivity between the dorsolateral prefrontal cortex and the caudate was associated with 
cognitive deficits in pre-HD individuals, whereas diagnosed HD participants had altered 
functional connectivity between the putamen and motor areas including the pre-motor 
cortex. Taken together, these findings suggest that putamen degeneration may provide a 
specific target for future clinical trials and may also be a putative target for intervention 
therapies. Alternatively, understanding of basal ganglia circuitry suggests that putamen 
circuitry is more involved in motor dysfunction whereas caudate circuitry may be more 
involved in cognitive and behavioral circuitry. It is possible that our findings would change 
were the diagnosis of HD based on cognitive, as well as motor, symptoms.
Our findings also underscore the importance of the pre-motor area, as structural connectivity 
between the premotor area and the striatum appears to be more severely affected than 
connectivity between the primary motor cortex or primary somatosensory cortex and the 
striatum. There were no disease-related changes in DTI measures in tracts connecting 
primary motor or primary somatosensory cortex to the caudate; however disease-progression 
related changes in DTI measures were present in the premotor area-caudate tract. Similarly, 
while there were significant alterations in all six tracts connecting to the putamen, 
differences in the premotor area-putamen tracts showed disease-related alterations in more 
DTI measures for both the Medium and High CAP groups, suggesting that these tracts were 
particularly susceptible to disease-related degeneration at baseline and longitudinally. 
Interestingly, while the right hemisphere premotor-putamen tract did show some group 
differences in DTI measures at baseline, it was particularly sensitive to longitudinal changes 
in DTI measures related to disease state, which suggests that this tract may be of particular 
interest for future studies.
The simplest explanation for the predominance of the premotor area in our findings is that it 
may be more strongly connected to the striatum than primary motor or somatosensory 
cortices. However, as part of our analysis of the DTI data, we estimated the number of 
streamlines within each tract and found that there were fewer streamlines connecting the 
premotor area with the striatum than there were connecting the other cortical areas to the 
striatum, which suggests that premotor area tracts dominated our findings for a different 
reason. Another possibility is that the specific areas of the putamen that receive premotor 
afferents may undergo degeneration at a different rate than other areas of the putamen. For 
example, primary motor cortex is known to connect to lateral regions of the putamen, while 
the premotor area connects with medial regions [Leh et al., 2007] which have been shown to 
degenerate earlier [Muralidharan et al., 2014; Younes et al., 2014]. Likewise, it is possible 
that connectivity between the primary motor and sensory cortices and the striatum is closely 
tied to the direct basal ganglia pathway while the premotor cortex is more closely associated 
with the indirect pathway, and so may be directly affected in HD. Either of these 
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explanations would support the idea that premotor-putamen connectivity is particularly 
susceptible to degeneration in pre-HD and would support the use of DTI measurements in 
this tract as a measure of disease progression.
Limitations
The main limitation of this study is that the PREDICT-HD study required that subjects had 
undergone predictive testing for the CAG expansion prior to enrollment in the study. It is 
unknown whether the subjects who volunteered for this study represent a random sample of 
all pre-HD subjects. The predictive testing rates are relatively low (10%–25%) so we cannot 
necessarily generalize to those who chose not to be tested prior to manifestation of the 
clinical phenotype.
Methodological variability due to differences in scanners, acquisition parameters, etc., 
presented a significant challenge. We have attempted to account for this variation with the 
robust and carefully considered processing methods documented in the publicly available 
processing pipeline (BRAINSTools suite, https://github.com/BRAINSia/BRAINSTools.git). 
Furthermore, careful consideration was taken in our selection of imaging data and in the 
selection of variables to include as covariates in our statistical modeling.
Conclusion
In the largest longitudinal study to date, we used longitudinal modeling to identify 
differences in DTI measures that were related to disease progression in pre-HD individuals 
within cortico-striate tracts originating in motor and sensory areas of the cortex. We 
identified differences in both the baseline and longitudinal imaging measures that were 
consistent with white matter degeneration and were most prevalent in pre-HD individuals 
who were closest to motor diagnosis. These differences also indicated that white matter 
degeneration occurred more than a decade prior to motor diagnosis. These changes 
predominantly involved connectivity in the premotor cortex and the putamen. Given the role 
of these regions in motor function specifically; these findings suggest a unique role for white 
matter loss between the affected regions in the onset of the HD motor symptoms needed for 
diagnosis. Furthermore, the relationship between DTI measures and disease progression was 
distinct from the relationship between striatal volume and disease progression in several of 
our tracts of interest, suggesting that DTI measures may provide unique information about 
the time-course and diagnosis of neurodegeneration in pre-HD.
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Figure 1. 
Tracts of interest shown with connections to: the primary motor cortex (blue), pre-motor 
area (yellow), and primary sensory cortex (red). The tracts with putamen (left) and caudate 
(right) termination are presented for each cortex region of interest. Tractography 
visualization was performed in 3D Slicer using SlicerDMRI.
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Figure 2. 
Matrix showing cross-sectional (A) and longitudinal (B) differences in DTI measures for 
each tract and DTI measure illustrating contrasts between pairs of CAP groups. Significant 
contrasts are shown in dark red-orange (P <0.05) or red (P <0.01). PMA: Premotor area, M1: 
Primary Motor Cortex, S1: Sensory Cortex, P: Putamen, C: Caudate.
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